Projektet Porösa läkemedelsbärare för inhalerbara terapier har nyligen startat upp

Det är finansierat av KK-stiftelsen och är ett samarbete mellan Biofilms – Research Center for Biointerfaces på Malmö Universitet, Iconovo AB och Nanologica AB. Nästa steg är att rekrytera en post doc. Iconovo kommer att bidra med sina egenutvecklade torrpuverinhalatorer (DPIs), inhalationsdevice, karakteriseringar av inhalationsberedningar liksom sin generella expertis inom inhalerade läkemedel.

Läs mera här

Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials

ICOcap™ is now available for customers to use in clinical trials that develop capsule-based formulations and can be bought from Stevanato, the manufacturing and distribution partner of Iconovo. The CE mark is applied in conformity with the requirements of Directive 93/42/EEC as a Class 1 Medical Device in collaboration with our partners Stevanato Group and their affiliate Balda Medical GmbH.

Read more

Positive patent news for Iconovo’s multidose inhaler

The European Patent Organization, EPO, has announced the intention to grant a patent regarding Iconovo’s inhalation device, ICOres. Iconovo has previously three granted Swedish patents and two granted European patents (EPO) on ICOres. The new patent covers the technology used in many of Iconovo’s projects like generic Symbicort©.

“This patent provides protection of a very important and fundamental function in ICOres. This additional patent strengthens our intellectual property and increases the value of our product portfolio”, says Johan Wäborg, CEO.